RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer

BACKGROUND: Oestrogen Receptor 1 (ESR1) mutations are frequently acquired in oestrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who were treated with aromatase inhibitors (AI) in the metastatic setting. Acquired ESR1 mutations are associated with poor prognosis and there is a l...

詳細記述

保存先:
書誌詳細
出版年:Br J Cancer
主要な著者: Dustin, Derek, Gu, Guowei, Beyer, Amanda R., Herzog, Sarah K., Edwards, David G., Lin, Hangqing, Gonzalez, Thomas L., Grimm, Sandra L., Coarfa, Cristian, Chan, Doug W., Kim, Beom-Jun, De La O, Jean-Paul, Ellis, Matthew J., Liu, Dan, Li, Shunqiang, Welm, Alana L., Fuqua, Suzanne A. W.
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782501/
https://ncbi.nlm.nih.gov/pubmed/33257837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01174-z
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料